marginally significantP = 0.089
CDK12 inactivating mutations were enriched in EAS ancestry in prostate cancer (Supplementary Table 1 ) and were marginally significant after adjusting for metastatic status available in the MSK-IMPACT cohort only ( P = 0.089, OR = 2.195).